University of Edinburgh Featured PhD Programmes
University of Oxford Featured PhD Programmes
University College London Featured PhD Programmes

Novel approaches for the treatment of dry eye disease

RCSI StAR International PhD Programme Research Projects

This project is no longer listed on and may not be available.

Click here to search for PhD studentship opportunities
Dr J Gabhann , Prof C Murphy Applications accepted all year round Self-Funded PhD Students Only

About the Project

Inflammation is a key unifying factor for a range of ocular surface inflammatory diseases including autoimmune mediated dry eye disease (DED) and complications with corneal transplantation (CT). While each condition has a specific presentation there are elements of overlapamong them, most strikingly (i) immune-mediated inflammation driving disease pathology (ii) use of immune suppression/corticosteroids as a primary treatment option (iii) lack of mechanisms to effectively deliver therapeutics to the ocular surface and (iv) no diagnostic tests that allow identification of patients who will go on to develop further complications. Current therapies for DED, including artificial tears and antiinflammatory agents, have been proved largely inadequate as they fail to address the underlying inflammatory component. Recently non-coding microRNA species have been shown to regulate inflammation. Synthetic DNA sequences that mimic or antagonise miR function are a new class of drugs which exhibit enhanced stability, target specificity and bioactivity.

An ability to effectively modulate miR function and thus ocular inflammation has wide ranging therapeutic and commercial implications. This proposal aims to address these needs by identifying bio-markers and targeting the molecular mechanisms that underpin DED disease pathology, with a strong emphasis on translational application of these findings to develop both diagnostics and novel therapeutics. Wehave generated promising preliminary data from epigenetic studies in Sjogrens Syndrome (SS) patients, who present with severe autoimmune mediated DED, where we have identified novel microRNAs (miRs) that contribute to ocular inflammation and the development of DED. We will build upon these findings and the strengths of our multidisciplinary team to progress personalised medicine in ocular surface diseases by developing and optimising an idealised medical device for effective and targeted delivery of anti-inflammatory agents to the ocular surface, which will lead to critical improvements in healthcare in areas of societal and economic burden, generating health and economic impact.

Funding Notes

Thank you for your interest in carrying out a research project with us in the School of Pharmacy and Biomolecular Sciences in RCSI. The deadline for application is now closed. In order to help us identify the right funding path to secure a postgraduate research position with us, can you let us know whether you are in a position to self-fund or are able to seek funding from government sources in your country. This will help us to assist you in any document preparation to apply for funding to carry out a postgraduate project with us.
Search Suggestions

Search Suggestions

Based on your current searches we recommend the following search filters.

FindAPhD. Copyright 2005-2020
All rights reserved.